What this site is — and what it is not

What this site is

Retatrutide Telehealth Digest is an independent editorial project that publishes summaries of the peer-reviewed research literature on retatrutide (LY3437943). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The word "telehealth" in this site's domain name is an SEO domain — it captures search traffic from people looking for telehealth-related information about retatrutide. It does not represent this site's function. No healthcare service, consultation, prescription, or referral is offered here. The name of the editorial brand is "Retatrutide Telehealth Digest" — the word "Digest" is the operative noun.

What we publish and how

Every quantitative claim on this site is cited to a specific peer-reviewed publication or registered clinical trial. The references index on each page lists the full citation for every claim, with DOIs and PubMed links where available. Citations are drawn from the published research record — no proprietary databases, no gray-literature sources, and no invented or unverifiable claims.

When we summarize community-reported effects (on the Effects page), we label them clearly as anecdotal — meaning they come from unverified self-reports in research-use communities and should not be treated as clinical evidence. The distinction between a peer-reviewed trial finding and a community report is explicit throughout.

This site covers only one compound: retatrutide, the investigational triple GIP/GLP-1/glucagon receptor agonist being developed by Eli Lilly. The site's pharmacokinetics lens — half-life, dosing windows, and the Phase 1b data that established them — reflects the documented emphasis of the compound-corpus that informs the editorial selection.

What we are not

We are not a telehealth provider. We do not connect patients with clinicians. We do not offer consultations, treatment plans, or prescriptions.

We are not a pharmacy. We do not dispense, compound, or supply retatrutide or any other compound.

We are not a vendor. We do not sell or link to suppliers of research-labeled material.

We are not affiliated with Eli Lilly and Company. The research record we summarize belongs to the public scientific literature; our editorial commentary is independent.

If you are looking for a healthcare provider for weight management or metabolic health, consult a licensed clinician.

On the investigational status of retatrutide

Every page on this site restates the same foundational fact: retatrutide is investigational. It is not FDA-approved. It is not approved anywhere. It cannot be prescribed or legally dispensed outside of a clinical trial.

We document this fact consistently because the landscape around this compound is noisy — gray-market vendors, incomplete secondary reporting, and colloquial misnomers (like "GLP-3") circulate widely. This site's editorial purpose is to hold the research record steady: what the trials measured, what was published, and where the genuine open questions remain.